vimarsana.com
Home
Live Updates
Roivant and Priovant Announce Results from Phase 2 Study of Oral Brepocitinib in Systemic Lupus Erythematosus : comparemela.com
Roivant and Priovant Announce Results from Phase 2 Study of Oral Brepocitinib in Systemic Lupus Erythematosus
Oral brepocitinib failed to meet its primary endpoint of Systemic Lupus Erythematosus Responder Index change of 4 at Week 52Priovant plans to continue progressing the program in indications outside...
Related Keywords
London ,
City Of ,
United Kingdom ,
Switzerland ,
Matt Gline ,
Stephanie Lee ,
Roivant Sciences ,
Securities Exchange ,
Exchange Commission ,
Systemic Lupus Erythematosus Responder Index ,
Systemic Lupus Erythematosus ,
Securities Act ,
Securities Exchange Act ,
Risk Factors ,
Markets ,
comparemela.com © 2020. All Rights Reserved.